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Abstract Objective To propose and assess a composite endpoint (CE) of neonatal benefit based
on neonatal mortality and morbidities by gestational age (GA) for use in preterm labor
clinical trials.
Study Design A descriptive, retrospective analysis of the Medical University of South
Carolina Perinatal Information System database was conducted. Neonatal morbidities
were assessed for inclusion in the CE based on clinical significance/risk of childhood
neurodevelopmental impairment, frequency, and association with GA in a mother–
neonate linked cohort, comprising women with uncomplicated singleton pregnancies
delivered at 24 weeks’ GA.
Results Among 17,912 mother–neonate pairs, neonates were at a risk of numerous
severe but infrequent morbidities. Clinically important, predominantly rare events
were combined into a CE comprising neonatal mortality and morbidities, which
decreased in frequency with increasing GA. The highest CE frequency occurred at
<31 weeks. High frequency of respiratory distress syndrome, bronchopulmonary
dysplasia, and sepsis drove the CE. Median length of hospital stay was longer at all
GAs in those with the CE compared with those without.
Conclusions Descriptive epidemiological assessment and clinical input were used to
develop a CE to measure neonatal benefit, comprising clinically meaningful outcomes.
These empirical data and CE allowed trials investigating tocolytics to be sized appropriately.
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In 2010, 11% of live births worldwide were preterm (occur-
ring before 37 weeks of gestation).1 Variation in estimated
preterm birth rates was seen across countries, from approxi-
mately 5% in Europe to 18% in Africa.1 While approximately
one-third of preterm births result frommedical intervention
to resolve maternal or fetal medical indications, 40 to 45%
result from spontaneous preterm labor, the underlying
pathogenesis of which is not fully understood.2 Preterm
birth is the most common direct cause of neonatal death
and indirectly affects infant mortality rates through asso-
ciated morbidities.3–5 Consequences for the neonate can
persist into later life, with sequelae such as visual and
hearing impairment, lung disease, cardiovascular disorders,
and neurodevelopmental impairments.3,6–9 Preterm birth
also imposes a substantial socioeconomic burden on families
(cost of care, loss of wages, and emotional impact) andwider
society (acute and chronic health-care costs).7
The global burden of preterm birth highlights the need for
effective drugs to stop preterm labor, and, as such, tocolytic
development is a discovery research priority of the World
Health Organization’s Every Newborn Action Plan to End
Preventable Deaths.10 The goal of current tocolytics for the
management of preterm labor is to prolong gestation, allow-
ing time for the administration of antenatal corticosteroids
ormaternal transfer to anothermedical facility,11 but there is
very limited evidence of ameasurable benefit of tocolytics on
neonatal outcomes.7,12 However, in considering atosiban for
the treatment of preterm labor, the U.S. Food and Drug
Administration stated that demonstrating prolongation of
pregnancy was no longer sufficient for the approval of new
tocolytics; randomized controlled trials (RCTs) of tocolytics
should have a primary endpoint of neonatal benefit. Preterm
birth study endpoints vary widely; a recent systematic
review reported 72 different primary outcomes in 103
RCTs among diverse patient populations.13 The majority
measured delay to delivery or perinatal mortality, and only
five studies used a composite endpoint of neonatal morbid-
ities and death, defined differently among each study.13 In
addition, there are sparse empirical data available in the
literature on the incidence of composite endpoints across the
spectrum of gestational age (GA).
Small population sizes are common in preterm birth RCTs,
and the infrequency of some severe morbidities underscores
the need for a suitable composite endpoint to establish
neonatal benefit. The European Network for Health Technol-
ogy Assessment states that composite endpoints are appro-
priate in clinical trials in the absence of a single suitable
primary endpoint. Moreover, there should be empirical and
clinical evidence of the value of each component, and com-
ponents should not be included in the composite if treatment
is not expected to affect this variable.14
Clinical development of new tocolytics (such as retosiban
currently in development by GlaxoSmithKline15,16) is
required to demonstrate both prolongation of pregnancy
and a benefit to the neonate. To inform the retosiban clinical
trial program, the objective of this study was to use real-
world empirical data to determine the frequencies of neo-
natal morbidities and mortality by GA in the patient popula-
tion of interest and to propose a clinically meaningful
composite endpoint to measure neonatal benefit in RCTs.
Material and Methods
Data Source and Patient Population
The study data source was the Medical University of South
Carolina (MUSC) Perinatal Information System (PINS), a
research-quality perinatal database for all women delivering
at the MUSC, which is a regional tertiary referral hospital in
the southeasternUnited States. An active surveillance system
was used to populate the MUSC PINS, in which data were
abstracted from clinical notes specifically for entry into the
database. Data were entered by trained personnel, and
logical error checks were performed routinely on all data;
inter- and intrarater reliability both exceed 97%.17 TheMUSC
PINS database included detailed information on each
mother’s medical history, linked to neonatal data (such as
medical diagnoses, medications, surgical procedures, and
laboratory tests) from delivery to hospital discharge; how-
ever, comprehensive antenatal care information from out-
side the hospital setting was not available. Ethical approval
for this studywas provided by the Institutional Review Board
for Human Research at the MUSC.
A descriptive, retrospective cohort study of the MUSC
PINS data was conducted from 2000 to 2011. The study
cohort (termed simulated trial population) was created to
match, as closely as possible within the constraints of the
database, the population within the phase III retosiban
clinical trials which was women with singleton uncompli-
cated pregnancies and intact membranes in preterm labor
between 240/7 and 336/7 weeks of GA (►Fig. 1). Women
with multiple gestation pregnancies were excluded. Mater-
nal pregnancy complications, as determined by trial exclu-
sion criteria, were preterm prelabor rupture of membranes,
hypertensive disorders of pregnancy (including severe
preeclampsia and eclampsia-related conditions), placental
conditions (such as placenta previa and placental abrup-
tion), and intra-amniotic infection or intrauterine growth
restriction (see ►Fig. 1 for full list of maternal complica-
tions used as exclusion criteria). Neonates with prespeci-
fied severe or life-threatening congenital conditions were
also excluded (►Fig. 1). As antenatal care was not captured
within the MUSC PINS, preterm labor diagnoses were not
available and therefore did not form part of the inclusion
criteria. All mother–neonate pairs who met the aforemen-
tioned inclusion and exclusion criteria and delivered at
24 weeks’ GA were included in the simulated trial popu-
lation (►Fig. 1).
Definition of Composite Endpoint
Clinical/Epidemiological Assessment of Data
The study investigated the frequency of approximately 100
neonatal outcomes (including neonatal medical diagnoses,
surgical procedures, medication use, laboratory tests) by GA
in the MUSC PINS database. The decision to consider further
or to exclude each neonatal outcome in a potential composite
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was made by the authors, additional members of the
GlaxoSmithKline clinical team, and a consulting neonatol-
ogist (as detailed in the Acknowledgments section). They
reviewed each of the outcomes and assessed its clinical
significance, frequency of occurrence, association with
GA, variability of diagnosis, and severity (particularly the
associated risk of neurodevelopmental impairment), as well
as published literature. Morbidities were considered for
inclusion in the composite if they were of particular clinical
relevance, such as predictors of long-term neurodevelop-
mental impairment; this was not dependent on their
reported frequency.
Used for composite
endpoint and
mortality analyses
all uncomplicated births
n = 17 957
all live births ≥24 weeks GA
from 2000–2011
n = 26 495 
Neonates who died 
before hospital discharge,
excluding those with 
AND excluding those 
born to mothers with 
n = 45
(0.2% of singleton births)
Neonates with congenital
or chromosomal 
n = 858
(3.5% of singleton births)
Women with
n = 5935
(24.3% of singleton births)
n = 2105
• Twins: n = 1935
• Triplets+: n = 170Singleton births
n = 24 390
Used for component
frequency analysis
(live born singletons
excluding all neonates with
congenital anomalies
AND those who died prior
to discharge AND those
born to mothers with
n = 17 912
• Severe pre-eclampsia: n = 980 (4.0%)
• Eclampsia: n = 37 (0.2%)
• HELLP syndrome: n = 148 (0.6%)
• IUGR: n = 1030 (4.2%)
• Polyhydramnios: n = 307 (1.3%)
• Oligohydramnios: n = 750 (3.1%)
• pPROM: n = 2264 (9.3%)
n = 1101 (4.5%)
• Placenta previa: n = 220 (0.9%)
n = 236 (1.0%)
Fig. 1 Patient attrition from the complete MUSC PINS database population to the simulated trial population for analyses. Maternal
complications (as listed in the correspondingly labeled box) were not mutually exclusive and therefore women could have more than one
complication. Congenital abnormalities were achondrogenesis type II, anencephaly, arteriovenous malformation, autosomal recessive
polycystic kidney disease, bilateral dysplastic kidneys, bilateral multicystic kidneys with renal failure, bilateral renal agenesis, congenital
hydrocephaly, congenital renal abnormality/agenesis, diaphragmatic hernia, duodenal atresia, exencephaly, exstrophy of bladder, gastroschisis,
genitourinary cystic/dysplastic obstruction, harlequin fetus, hydronephrosis, hydrops fetalis (immune and nonimmune), hypoplastic left heart,
imperforate anus, inborn error of metabolism, iniencephaly, Meckel–Gruber’s syndrome, mixed dysplastic/cystic/agenic disorders with kidney
failure, myelomeningocele, esophageal atresia, omphalocele, osteogenesis imperfecta type II, Potter’s syndrome, tetralogy of Fallot, total
anomalous pulmonary venous return, tracheoesophageal fistula, transposition of the great arteries, trisomy 13, trisomy 18, and trisomy 21. GA,
gestational age; HELLP syndrome, hemolysis, elevated liver enzymes, low platelet count; IUGR, intrauterine growth restriction (defined as fetal
weight below the 10th percentile for GA); MUSC, Medical University of South Carolina; PINS, Perinatal Information System; pPROM, preterm
prelabor rupture of membranes.
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Components and Calculation of the Composite Endpoint
The followingmorbiditieswere identified as themost appro-
priate components for a composite endpoint to investigate
neonatal benefit of interventions to postpone preterm deliv-
ery based on their clinical significance and relationship with
early GA: fetal/neonatal death, respiratory distress syndrome
requiring continuous positive airway pressure ormechanical
ventilation, bronchopulmonary dysplasia (BPD), severe
intraventricular hemorrhage (grade 3 or 4), periventricular
leukomalacia (with periventricular cyst or with porencepha-
lic cyst or acquired hydrocephaly), retinopathy of prematur-
ity (confirmed as stage 3 or any stage requiring laser
treatment), confirmed sepsis, meningitis, and necrotizing
enterocolitis (surgically treated).
To calculate the overall frequency of the composite end-
point, the data for each individual neonate were assessed. For
any individual, if any of themorbiditieswere present, then the
score was 1, otherwise the score was 0; the scores from all
individualswere summedbyweekof GA to form aGA-specific
count or numerator (by individual week). The denominator
population was the simulated trial cohort (►Fig. 1) but
included neonates who died, as death was an outcome in
the composite; denominators were also calculated by week of
GA. Deaths were defined as all deaths before hospital dis-
charge, including antepartum and intrapartum deaths.
Composite endpoint frequencies were also stratified by sex
and race. This stratification allowed the endpoint to be evalu-
ated against established neonatal morbidity associations.18,19
Statistical Software
All analyses were conducted in SAS version 9.3 (SAS Institute
Inc., Cary, NC, United States).
Results
Study Population Characteristics
The overall MUSC population comprised 26,495 women;
population attrition from the overall population extracted
from the MUSC PINS database and reasons for patient exclu-
sion (as well as details of complications and abnormalities
resulting in exclusion from the cohort) are detailed in►Fig. 1.
From the overall population, 17,912 mother–neonate pairs
were included in the simulated trial population (67.6%).
Maternal demographics of the simulated trial population are
shown in ►Table 1. Women in the study had a mean age of
26 years (standard deviation: 6.1 years; range: 13–51 years),
and almost half of the populationwere black (44.7%). Just over
half were on government-funded social welfare for low-
income individuals (Medicaid/public/medically indigent;
52.7%) and a third (33.8%) had 13 years education, equating
toauniversityorotherhigher-level education. In thesimulated
trial population, 8.2% of the births were preterm in contrast to
28.5% of the overall population (data not shown), indicative of
the high-risk referral status of the hospital.
Neonatal demographic characteristics and composite
morbidities of the simulated trial population are shown
in►Table 2 and►Fig. 2A, with rates of additionalmorbidities
in ►Supplementary Table S1 (online only). As expected, a
Table 1 Characteristics of women in the simulated trial
population in the MUSC PINS between 2000 and 2011
Characteristic N %a
Overall N ¼ 17,912
Maternal age (y)a
12–18 853 8.6
19–29 6,286 63.3
30–39 2,574 25.9
 40 212 2.1
Unknown 7,987
Maternal race
White 4,997 27.9
Black 8,011 44.7
Hispanic 4,557 25.4
Other 347 1.9
Health insurancea–c
Commercial/private 4,083 22.8
Self-pay 4,393 24.5
Medicaid/public/medically
indigent
9,435 52.7
Education levela
 12 y 8,416 66.2
 13 y 4,298 33.8
Unknown 5,198
GA at birth (wk)
24–27 136 0.8
28–33 445 2.5
34–36 888 5
 37 16,443 91.8
Maternal medicationsd
Tocolysis (included
MgSO4, terbutaline,
indomethacin, nifedipine,
ritodrinee)
300 51.6
Antenatal steroids (included
betamethasone or
dexamethasone)
487 83.8
Abbreviations: GA, gestational age; MUSC, Medical University of South
Carolina; PINS, The MUSC Perinatal Information System.
Note: Rounding of percentages of patients may result in characteristic
groups summing to >100.
aPercentage calculated only among those with known data. bOne
woman with unknown insurance status. cIn the United States, health
insurance is required to pay for medical expenses (commercial/private
insurance is employer-funded, self-pay is payment at the point of care,
Medicaid/public/medically indigent insurance is government-funded,
social welfare for low-income individuals). dPercentage calculated
among the 581 women with neonates of <34 weeks’ GA only
(indicated population). eRitodrine was discontinued in the United
States in March 2010.
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clear relationship was seen with GA for both neonatal ward
use and length of hospital stay (birth hospitalization). All
extremely preterm babies (24–27 weeks’ GA) required level
III neonatal intensive care unit (NICU) treatment, and 25.7%
were hospitalized for 3 months. Similarly, almost 98% of
moderately preterm babies (28–33 weeks’ GA) required level
II/III NICU care, and >30% remained in the hospital for 1
month.
Neonatal Morbidities and Composite Endpoint
Development
In total, 3.4% of the population were positive to the compo-
site endpoint. Of those with the composite endpoint, 84.9%
were born preterm compared with 5.6% without the com-
posite. The frequency of the composite endpoint and the
individual frequencies of neonatal mortality andmorbidities
by individual week of GA at delivery are shown in ►Fig. 2A.
The frequency of the composite and all component morbid-
ities decreased steeply with increasing GA, with the highest
frequency of morbidity seen before 31 weeks, dropping to
very few events in the full-term population (37 weeks). For
the majority of other key neonatal morbidities, a similar
inverse relationship was seen with increasing GA, with most
events among the extremely and moderately preterm
infants. The exception to this was hypoglycemia, which
occurred in approximately 15 to 22% in each of the preterm
groups (►Supplementary Table S1, online only).
The frequency of the composite was driven by the fre-
quency of respiratory distress syndrome, BPD, and sepsis.
Respiratory distress syndrome was the most frequent mor-
bidity at every GAweek, apart from 35 and 36 weeks, where
BPD was more common. Other components were rarer,
occurring between 3 and 12% of the extremely premature
(24–27 weeks) group, and 1 and 3% of the moderately
preterm group (28–33 weeks’ GA). When race (black, white)
and sex stratification by GA was performed, there was
considerable variability in the composite endpoint fre-
quency, particularly between 27 and 36 weeks’ GA in each
subgroup; after 37 weeks, the composite frequency was
similar between these subgroups (►Fig. 2B). While the
Table 2 Neonatal characteristics in the simulated trial population
GA at birth (wk)a
Neonatal variable 24–27
(n ¼ 136)
28–33
(n ¼ 445)
34–36
(n ¼ 888)
37
(n ¼ 16,443)
Total
(N ¼ 17,912)
Neonatal sex, n (%)
Male 79 (58.1) 232 (52.1) 465 (52.4) 8,353 (50.8) 9,129 (51)
Female 57 (41.9) 213 (47.9) 423 (47.6) 8,090 (49.2) 8,783 (49)
Neonatal race, n (%)
White 46 (33.8) 147 (33) 264 (29.7) 4,510 (27.4) 4,967 (27.7)
Black 82 (60.3) 268 (60.2) 470 (52.9) 7,196 (43.8) 8,016 (44.8)
Hispanic 8 (5.9) 27 (6.1) 146 (16.4) 4,385 (26.7) 4,566 (25.5)
Other 0 3 (0.7) 8 (0.9) 352 (2.1) 363 (2)
Highest level neonatal ward admission during hospital stay, n (%)
Normal nursery (level I) 0 10 (2.2) 536 (60.4) 15,141 (92.1) 15,687 (87.6)
NICU level IIb 0 149 (33.5) 246 (27.7) 938 (5.7) 1,333 (7.4)
NICU level IIIc 136 (100) 286 (64.3) 106 (11.9) 359 (2.2) 887 (5)
Length of hospital stay, n (%)
< 3 d 0 8 (1.8) 443 (49.9) 12,899 (78.4) 13,350 (74.5)
3 d to 1 wk 1 (0.7)d 40 (9) 331 (37.3) 3,290 (20) 3,662 (20.4)
1 wk to 1 mo 0 245 (55.1) 106 (11.9) 212 (1.3) 563 (3.1)
1–2 mo 42 (30.9) 128 (28.8) 6 (0.7) 31 (0.2) 207 (1.2)
2–3 mo 58 (42.6) 20 (4.5) 0 7 (0) 85 (0.5)
 3 mo 35 (25.7) 4 (0.9) 2 (0.2) 4 (0) 45 (0.3)
Abbreviations: GA, gestational age; NICU, neonatal intensive care unit.
aGA was analyzed by week but is summarized here by range for clarity. bNICU level II is a special care nursery providing care for neonates born at32
weeks’ GA and weighing  1,500 g who are physiologically immature or are moderately ill with problems that are expected to resolve rapidly
without urgent subspecialty services. cNICU level III can provide sustained life support, provide comprehensive care for neonates born at<32weeks’
GA and weighing<1,500 g or neonates of any GA/birth weight with critical illness, give ready access to pediatric specialists including surgeons, can
provide respiratory support including ventilation and inhaled nitric oxide, and perform emergency advanced imaging. dNeonate transferred to
another hospital for continued care at day 7.
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smaller sample sizes in the subgroupsmay partly explain the
variability between GA groups, overall trends can be seen.
The frequency of the composite in black neonates of either
sex tended to be below the rate seen for the overall popula-
tion, whereas white neonates had composite rates slightly
higher than those in the overall population, though this was
not statistically determined.
Median length of stay of the birth hospitalization was
consistently longer at each week of GA among those with the
composite endpoint compared with those without (►Fig. 3).
It fell sharply from 102 days (interquartile range [IQR]: 88–
116) at 24weeks’GA to 6 to 8 days at 36 to 38weeks’GA, after
which a slight upturn was seen. The composite was not
present in only seven neonates before 30 weeks’ GA; median
length of stay was 29 days (IQR: 21–34) at 30 weeks’ GA,
dropping to 2 days (IQR: 1–2) at 35 weeks and remaining at
this level thereafter.
Discussion
Current tocolytic agents do not necessarily demonstrate
neonatal benefit, despite often successfully prolonging preg-
nancy.11 As a result, it is now recommended that preterm
labor RCTs should have an additional primary endpoint of
neonatal benefit.20 Despite this, there are no standard end-
points in clinical trials involving women who might deliver
preterm neonates.13,17,21 The Core Outcomes for Prevention
of Preterm birth project led by the Core Outcomes in
Women’s Health initiative aims to obtain expert consensus
about the most relevant and clinically meaningful endpoints
in this field to facilitate effective synthesis of evidence in
RCTs and help develop robust recommendations for clinical
practice.22 These initiatives will be valuable in providing
expert clinical opinion regarding the core outcomemeasures
of neonatal benefit in preterm birth; however, it is also
important to provide empirical evidence of the frequency
of the proposed endpoints in similar populations to that of an
RCT, hence the use of real-world data in this study.
Data from this study were used to directly inform sample
size planning for the ongoing retosiban clinical trials, as the
database hospital site closely resembles the study centers for
the RCT program.We took into consideration that, because of
the stipulated population characteristics, theMUSC rates are
likely to represent the upper limit of plausibility of those
seen in RCTs. However, this similarity between the popula-
tions should maximize the likelihood of appropriate study
power to determine neonatal benefit; indeed, an earlier
preterm birth intervention study noted that the use of
historical data from dissimilar study centers might have
been at least partly responsible for negative results.23 Repli-
cation of the frequency of this composite endpoint and
individual neonatal morbidities is ongoing using other U.S.
and European databases.
In this study, data were descriptively analyzed from a
cohort of almost 18,000 mother–neonate pairs identified
from the MUSC PINS database, and components of the
proposed composite were selected following examination
of approximately 100 neonatalmorbidities. Neonateswere at
a risk of a range of severe but predominantly infrequent
morbidities, which suggested that it would be appropriate to
combine clinically meaningful rare events into a single
composite measure, particularly as morbidities rarely
occurred singly but were commonly clustered.
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The composite represents a set of important comorbid-
ities inversely associated with GA at birth and resulting in a
longer length of hospital stay. These morbidities are directly
related to recognized health burdens. Most of the included
morbidities substantially increase the risk of later neurode-
velopment impairment such as cerebral palsy, developmen-
tal delay, and visual/hearing impairments. For example,
BPD24 and necrotizing enterocolitis25 are direct risk factors
for neurodevelopment impairment, and intraventricular
hemorrhage, through its strong association with white mat-
ter damage, indirectly increases the risk of neurodevelop-
ment impairment.26
A strong inverse relationshipof the compositewith increas-
ing GAwas seen, and this declining incidence ofmorbidities is
in agreement with previous studies inwider populations.27,28
The largest variability in sex and race, also observed between
weeks 30 and 35, is consistent with previous studies.18,19 It is
well established that male neonates have a higher mortality
rate compared with female neonates,19 which was demon-
strated in this study. Moreover, black preterm neonates (>28
weeks’ GA) have the lowest mortality rate compared with
white or Hispanic neonates,18whichwas also reflectedwithin
this composite analysis.
This study has several limitations. The MUSC database
draws from a single center based in the southeastern
United States, with a predominantly black and lower socio-
economic status population. Marked variation in perinatal
and neonatal outcomes have been observed across different
regions and countries;29 therefore, the study population
used in this analysis may not be broadly generalizable to
that of a global RCT. However, the MUSC site does resemble
the proposed study centers in the retosiban RCT program
(i.e., hospitals with high-level NICU capabilities).15,16 The
study period spanned 11 years, over which time many
components of neonatal care have improved, which may
lead to reduced event frequency in more recently collected
data. A recent U.S. study indicated that mortality and rates of
several of the included morbidities (sepsis, intraventricular
hemorrhage, periventricular leukomalacia, and retinopathy
of prematurity) have decreased slightly between 1993 and
2012, though the rates of BPD did not.30 Further limitations
of the study include the risk for bias during chart abstraction
from medical records into the database; this was minimized
by using data abstractors with training in medical terminol-
ogy and implementation of strict guidelines on priority of
data abstraction when multiple sources were available. In
addition, data validity was further assessed by having a 10%
random sample of charts abstracted by a different neonatol-
ogist who was not working in the hospital at the time of
original data collection. The study population included all
women with singleton, uncomplicated pregnancies but not
those with a diagnosis of preterm labor (as would be
included in the trial) as this was not captured within the
database. Finally, within the clinical trial setting, outcomes
will be defined usingmore specific clinical criteria thanwere
able to be captured within a database, which may influence
the frequency of the morbidities (Supplementary Table S2
[online only] for trial versus database definitions).
Neonates in this descriptive analysis of a real-world single-
center database cohort were at a risk of several clinically
meaningful but predominantly infrequent morbidities. While
maintaining clinical relevance, we combined eight of these
morbiditieswithmortality into a composite endpoint. Use of a
composite endpoint may improve the statistical efficiency of
RCTs for tocolytics required to demonstrate neonatal benefit,
and the empirical data generatedwere used to directly inform
sample size calculations for such trials.
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